Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Plasma Apolipoprotein J As A Potential Biomarker For Alzheimer's Disease: Australian Imaging, Biomarkers And Lifestyle Study Of Aging, Veer Gupta, James D. Doecke, Eugene Hone, Steve Pedrini, Simon M. Laws, Madhav Thambisetty, Ashley Bush,, Christopher C. Rowe, Victor L. Villemagne, David Ames, Colin L. Masters, Stuart Lance Macaulay, Alan Rembach, Stephanie R. Rainey-Smith, Ralph N. Martins
Plasma Apolipoprotein J As A Potential Biomarker For Alzheimer's Disease: Australian Imaging, Biomarkers And Lifestyle Study Of Aging, Veer Gupta, James D. Doecke, Eugene Hone, Steve Pedrini, Simon M. Laws, Madhav Thambisetty, Ashley Bush,, Christopher C. Rowe, Victor L. Villemagne, David Ames, Colin L. Masters, Stuart Lance Macaulay, Alan Rembach, Stephanie R. Rainey-Smith, Ralph N. Martins
Research outputs 2014 to 2021
Introduction:
For early detection of Alzheimer's disease (AD), the field needs biomarkers that can be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also known as clusterin) has long been associated with AD pathogenesis through various pathways. The aim of this study was to investigate the potential of plasma apoJ as a blood biomarker for AD.
Methods:
Using the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the present study assayed plasma apoJ levels over baseline and 18 months in 833 individuals. Plasma ApoJ levels were analyzed with respect to clinical classification, age, gender, …
Comparing Biological Markers Of Alzheimer's Disease Across Blood Fraction And Platforms: Comparing Apples To Oranges, Sid E. O'Bryant, Simone Lista, Robert A. Rissman, Melissa Edwards, Fan Zhang, James Hall, Herik Zetterberg, Simon Lovestone, Veer Bular Gupta, Neill Graff-Radford, Ralph N. Martins, Andreas Jeromin, Stephen Waring, Esther Oh, Mitchel Kling, Laura D. Baker, Harald Hampel
Comparing Biological Markers Of Alzheimer's Disease Across Blood Fraction And Platforms: Comparing Apples To Oranges, Sid E. O'Bryant, Simone Lista, Robert A. Rissman, Melissa Edwards, Fan Zhang, James Hall, Herik Zetterberg, Simon Lovestone, Veer Bular Gupta, Neill Graff-Radford, Ralph N. Martins, Andreas Jeromin, Stephen Waring, Esther Oh, Mitchel Kling, Laura D. Baker, Harald Hampel
Research outputs 2014 to 2021
Introduction:
This study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms.
Methods:
Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots.
Results:
On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared > 50% of the variance across blood fractions (serum amyloid A R2 = 0.99, interleukin (IL)10 R2 = 0.95, fatty …